5-Amino-1MQ Side Effects

Reported 5-Amino-1MQ side effects

The side effect profile of 5-amino-1MQ in humans is not documented because there are no human clinical trials. Rodent studies report generally good tolerability at doses producing metabolic and muscle benefits, without obvious signs of hepatotoxicity, nephrotoxicity, or behavioral changes over the dosing periods studied (typically 4-12 weeks) ([Kannt et al., 2018]; [Neelakantan et al., 2019]). Rodent tolerability does not guarantee human tolerability, and the duration of rodent studies is short relative to the chronic dosing that longevity-oriented human users might pursue. Theoretical side effect concerns based on the mechanism include: methylation homeostasis disruption, where chronic NNMT inhibition alters methyl donor metabolism and could affect DNA methylation, histone methylation, and other methyltransferase-dependent processes in ways that may produce unpredictable long-term effects; cancer risk implications, which are complex — NNMT is overexpressed in some cancers (endometrial, pancreatic, others) where it may support tumor metabolism, suggesting NNMT inhibition could be beneficial or neutral in these contexts, but methyl balance alterations could theoretically affect tumor surveillance and susceptibility in ways that cannot be predicted from available data; cardiovascular effects, which are not characterized in human subjects — 1-MNA itself has been proposed to have cardioprotective effects in some studies, and reducing 1-MNA production by inhibiting NNMT could theoretically have cardiovascular consequences; hematologic effects, where NAD+ metabolism is relevant to red blood cell function and bone marrow activity, though rodent studies have not reported notable hematologic changes; hepatic effects, where the liver is a major NNMT-expressing tissue and inhibition may alter hepatic metabolism in ways that require monitoring; gastrointestinal effects, which have been reported anecdotally (nausea, mild abdominal discomfort) by some self-experimenters, likely reflecting oral exposure of gut tissue to the compound. Self-report data from research-chemical users of 5-amino-1MQ describe a generally well-tolerated compound with occasional mild nausea or digestive symptoms at higher doses, subjective changes in energy levels (both directions — increased in some users, fatigue in others), mild dry mouth, and rare reports of headache. These reports are unverified, unblinded, confounded by concurrent use of other compounds in most cases, and should not be treated as systematic safety information. The most important side effect concern for long-term users of any NNMT inhibitor is the methylation-homeostasis question. Methylation reactions are involved in: DNA methylation (gene expression regulation across the genome); histone methylation (chromatin state and gene expression); phospholipid methylation (phosphatidylcholine synthesis from phosphatidylethanolamine, which is important for membrane function and liver biology); neurotransmitter synthesis and inactivation (particularly catechol-O-methyltransferase regulating dopamine, epinephrine, norepinephrine); carnitine biosynthesis; creatine biosynthesis; and epinephrine synthesis from norepinephrine. Chronic alteration of methyl donor availability through NNMT inhibition could theoretically affect any of these processes, though the magnitude of effect at pharmacologic doses of 5-amino-1MQ is unknown. The NAD+ pathway effects of NNMT inhibition — preserving NAD+ for sirtuin activity and cellular energetics — are the intended positive consequences. The methyl-balance effects are a less obviously positive consequence, and the absence of long-term human data means we do not know whether chronic users of NNMT inhibitors develop problems related to methyl donor imbalance over years of use. For acute use at typical research-chemical doses over short cycles, significant adverse effects appear uncommon based on animal data and anecdotal human reports. For extended or indefinite use, the safety profile is unknown and extrapolation from short-term data is not reassuring. The appropriate monitoring for self-experimenters includes: baseline and follow-up comprehensive metabolic panel, complete blood count, liver function tests, and thyroid panel; lipid panel with ApoB if long-term use is planned; homocysteine measurement if methyl balance concerns are relevant (elevated homocysteine can indicate methyl donor depletion); vitamin B12 and folate to ensure adequate one-carbon metabolism support; and any condition-specific markers relevant to personal health status. Any unexplained abnormality should prompt cessation and evaluation. Overdose, in the sense of acute toxicity from a large single dose, has not been reported in the peer-reviewed literature. The compound is relatively novel, and the spectrum of acute toxicity has not been characterized in humans.

When to continue, reduce, or stop 5-Amino-1MQ

5-Amino-1MQ contraindications

5-Amino-1MQ has not been clinically tested, so the contraindications list is constructed from mechanism-based concerns and general principles for unvalidated research chemicals. Pregnancy and breastfeeding are absolute contraindications — no reproductive or developmental toxicology data exist, and the effects of altered methyl donor metabolism and NAD+ pathway modulation on placental function, fetal development, and lactation are entirely uncharacterized. Methyl donor balance is particularly critical during embryogenesis (neural tube development depends on adequate folate and methionine cycle function), which makes any intervention that alters methylation during pregnancy particularly risky. Anyone trying to conceive should avoid 5-amino-1MQ because reproductive effects are unknown. Children and adolescents should not use 5-amino-1MQ because developmental metabolism, bone and muscle growth, and neurological maturation depend on methylation and NAD+ pathways in ways that could be disturbed by NNMT inhibition, and these effects have not been studied in developmental age groups. Active malignancy is a relative contraindication with important nuance. NNMT is overexpressed in many cancers (endometrial, pancreatic, ovarian, lung, colorectal, others) where it may support tumor metabolism through methyl donor depletion and methylation remodeling. In principle, NNMT inhibition could be beneficial in cancers driven by NNMT overexpression, and there is academic interest in NNMT inhibitors as cancer therapeutics. However, uncontrolled self-administration of an NNMT inhibitor during active cancer treatment is not a substitute for properly designed oncology care, and the interaction with chemotherapy, radiation, and targeted therapies is not characterized. Patients with cancer should not use 5-amino-1MQ without explicit oncology guidance, and probably not even with it outside of a clinical trial context. Patients with a history of cancer under surveillance should similarly avoid 5-amino-1MQ because effects on dormant disease are unknown. Active cardiovascular disease is a relative contraindication because of uncharacterized effects on vascular biology. 1-methylnicotinamide (1-MNA), the product of the NNMT reaction that 5-amino-1MQ reduces, has been proposed to have cardiovascular effects (vasodilation, anti-inflammatory, anti-thrombotic) based on some animal studies, and reducing 1-MNA production through NNMT inhibition could theoretically alter these signals. Whether this translates to clinically meaningful cardiovascular effects in humans is unknown, but patients with coronary artery disease, heart failure, arrhythmias, or significant cardiovascular risk factors should err toward caution. Hepatic impairment warrants caution because the liver is a major NNMT-expressing tissue and hepatic methylation reactions are central to metabolic homeostasis. Patients with active hepatitis, cirrhosis, significant fatty liver with elevated enzymes, or prior drug-induced liver injury should avoid 5-amino-1MQ because liver stress responses and methylation homeostasis may be disrupted. Renal impairment warrants caution because drug elimination pathways are not characterized, and altered 1-MNA excretion (which is normally renal) could have systemic consequences in the setting of reduced renal function. Significant mental health conditions on medications with narrow therapeutic windows are a relative contraindication because methylation balance affects catechol-O-methyltransferase (COMT) activity and thus catecholamine metabolism, potentially altering drug levels for medications metabolized through these pathways. Patients on MAOIs, tricyclic antidepressants, clozapine, or other drugs with sensitive metabolism should consult their psychiatrist before adding any compound with methylation-pathway effects. Homocystinuria, methylenetetrahydrofolate reductase (MTHFR) deficiency, and other inborn errors of methylation metabolism are absolute contraindications because these conditions involve pre-existing methyl donor balance pathology that could be worsened by NNMT inhibition. Severe deficiencies in folate or B12 that have not been corrected are relative contraindications because methyl donor availability is already compromised. Patients on anti-epileptic medications with methylation sensitivity (valproate, others) should consult their neurologist. Medications with known interaction potential warrant particular attention. Anticoagulants: not a clear interaction, but any compound altering liver metabolism could theoretically alter warfarin metabolism through P450 effects; INR monitoring is prudent if warfarin is concurrent. Direct oral anticoagulants (apixaban, rivaroxaban, dabigatran) may be safer with respect to interactions but are not fully characterized. Antihypertensives: theoretical cardiovascular effects may alter blood pressure response; monitor blood pressure during use. Insulin and sulfonylureas: metabolic effects may reduce insulin requirements; monitor glucose to avoid hypoglycemia. GLP-1 agonists: metabolic overlap as discussed in the stacking notes; monitor for excessive effects. Chemotherapy agents: drug-drug interaction potential is uncharacterized; avoid unless under oncologist supervision. Any medication on which the patient has tight therapeutic range or known metabolic sensitivity warrants pre-use consultation. The final and most important contraindication is the absence of clinical oversight. Self-experimentation with 5-amino-1MQ without a physician who knows about the use, can order appropriate labs, can adjust or stop dosing based on findings, and can evaluate any adverse effects is not a defensible approach to safe experimentation. This applies even if the user feels healthy and has no known medical conditions — the value of clinical support is in detecting and responding to subclinical abnormalities before they become clinical problems, and that detection is not possible without ongoing monitoring. If you do not have a physician who knows you are using 5-amino-1MQ, you have not set up the minimum safety infrastructure for using an unvalidated research chemical.

Why vendor quality drives 5-Amino-1MQ side-effect frequency

Research-compound communities consistently report that adverse-event frequency tracks with source quality. Three reasons: (1) impurity profiles vary by lab (residual synthesis byproducts can trigger reactions); (2) mislabeled mass means actual dose can be 50-150% of stated dose; (3) reconstitution-grade water and capping methodology affect long-term storage stability. COA-verified vendors with published HPLC data minimize all three failure modes. Check a vendor's COA record and Trust Score before you buy.

5-Amino-1MQ side effects FAQ

Research-use disclaimer. All safety information on this page summarizes published research literature and community-reported reactions. It is not medical advice and not authorization for human consumption. Always consult a licensed practitioner before any compound enters a clinical context. Compounds linked from this page are sold for research-use only.
Affiliate disclosure. See our affiliate disclosure .